1800 244 735

Helpline (02) 9874 9777

mTORC1 tips the scales in Huntington’s disease mice

What happens when you have a broken part in a machine? You fix it! A new study shows that increasing the activity a critical piece of machinery called ‘mTORC1’ in a mouse model of Huntington’s disease leads to improved motor problems and brain abnormalities associated with the disease. These recently published findings may offer scientists a new target for therapeutic development in HD.

In search of new targets

Everyone has two copies of a gene that scientists call “Huntingtin” and people with Huntington’s Disease have inherited (at least) one mutant copy of this gene from either their mom or dad. The gene itself is not thought to be harmful, but rather what cells do with it. In general, cells use genes as instructions to guide the construction of little machines called proteins.

Like the gene, the protein made from it is called “Huntingtin”, which can be a bit confusing. The mutant huntingtin protein builds up over time and especially damages a brain region called the striatum. Inside the cells of this important brain region, the mutant huntingtin protein can interfere with many other bits of important machinery that influence how a cell grows and survives.

Malfunctions in the work of these little machines caused by mutant huntingtin is thought to underlie the disease. Because of this, many researchers focus their studies on finding the broken cogwheels in cells with mutant Huntingtin around. What changes can be observed when mutant huntington is present? If we fix those changes, does it lead to improvements in HD symptoms?

One of these targets was recently investigated by a team of scientists led by Dr. Beverley Davidson at the University of Iowa. The group’s research focused on a little machine called ‘mammalian target of rapamycin complex 1’ or mTORC1.

mTORC-What?

Now what exactly is this mTORC1? In order for cells to grow, divide, and survive, they must ensure that they carefully use their resources in the right way. If there’s lots of food around, the cells can happily spend energy. On the other hand, in times when resources are scarce, cells need to be much more conservative and save their energy.

This balance between using and conserving resources is where mTORC1 comes in. It sits in the middle of an elaborate set of machinery present in every cell, constantly ensuring that the amount of energy used is matched to the amount of energy coming in. In a way, the machinery controlled by mTORC1 is sort of like the cell’s banker, making sure that the books are balanced.

A broken machine

Previous work by other scientists had implicated changes in this energy balancing pathway in HD. To get more information about why this was happening, Davidson’s team first looked at the brains of HD patients and mouse models of the disease. They found evidence that the activity of the network controlled by mTORC1 was strongly reduced in the vulnerable parts of the brain in HD.

Next, they used viruses to deliver a powerful “on” signal to the resource control network in the brains of HD mice, artificially boosting the activity of mTORC1. When they did this, they could measure changes that showed them that their push had worked – the system was working more like it did in the brains of normal, non-HD, mice.

When mTORC1 activity was restored in the HD mice, brain areas that had begun to shrink and degenerate recovered. The treatment also positively affected movement behaviors, such as the ability to run on a rotating bar (a task that HD mice do not do well on). Many other problems often seen in HD mice were improved, including increased cellular energy production.

Davidson’s team also found that other pathways in the cell that have previously been shown to be defective in HD were improved by this treatment. One of these important pathways is called autophagy and is basically an organism’s biological ‘junk’ cleanup process. This is especially important because this autophagy pathway can help cells clear out mutant huntingtin itself, which might explain where all these benefits were coming from.

Interestingly, previous work had predicted just the opposite result – that increasing the activity of mTORC1 would lead to reductions in autophagy. Just why the opposite result was observed in HD brains is a bit of a mystery, one that will probably reveal new aspects of how cells work.

Excitingly, some of the benefits of increasing mTORC1 activity were seen even when mice were treated after they’d already gotten sick. These results are important because they show that brain cells are capable of responding to treatment even after disease onset.

Balancing act

While this work is very exciting science, it is important to note that the activities of these systems lie in a very delicate balance. An earlier study of mTORC1 in the muscles of HD mice revealed increased activation. You heard right – these are opposite findings.

If this is also the case in humans with HD, it could be very hard to find a way to change the activity levels of mTORC1 in different ways in different tissues. However, what is clear is that Dr. Davidson’s results suggest that mTORC1 pathway in the brain is impaired in HD, and that improving how the pathway functions as a protective effect.

What all of this research suggests is that the interaction between mTORC1 and huntingtin lies in a delicate balance and that repairing or restoring this pathway must be done at just the right level to avoid further harm. It’s a ‘Goldilocks effect’ where mTORC1 levels need to be just right – either too much or too little is harmful!

Tipping the scales

Much work still remains to translate these exciting scientific findings into a therapy. One major issue is just how complicated these systems and targets are for scientists to study. For example, other neurological disorders such as Fragile X syndrome and autism both feature overactive mTORC1 activity, while mTORC1 is reduced in ALS and HD.

This exciting new science also reminds us that it’s when we get unexpected results that we often learn the most interesting things. Answering the new questions raised by this study might open new avenues for developing novel therapies for HD.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more